细胞外囊泡与口腔肿瘤免疫

doi:10.13591/j.cnki.kqyx.2023.09.001

口腔医学 ›› 2023, Vol. 43 ›› Issue (9): 769-774.doi: 10.13591/j.cnki.kqyx.2023.09.001

• 述评 • 下一篇

细胞外囊泡与口腔肿瘤免疫

肖博林¹,张伟^1,²,陈刚^1,^2,³()

1 口颌系统重建与再生全国重点实验室,口腔生物医学教育部重点实验室,口腔医学湖北省重点实验室,武汉大学口腔医(学)院,湖北武汉(430079)
2 武汉大学泰康生命医学中心,湖北武汉(430071)
3 武汉大学免疫与代谢前沿科学中心,湖北武汉(430071)

修回日期:2023-07-02 出版日期:2023-09-28 发布日期:2023-09-28
通讯作者: 陈刚 E-mail:geraldchan@whu.edu.cn
陈刚,武汉大学口腔医学院主任医师、教授、博士生导师,武汉大学泰康生命医学中心PI,武汉大学免疫与代谢前沿科学中心兼职PI。武汉大学首届(2004级)口腔医学八年制本博连读生,2012年博士毕业,并留校工作至今。2013—2014年于武汉大学化学与分子科学学院从事博士后研究,2014—2017年于美国宾夕法尼亚大学生物学系从事博士后研究。2019年获批国家优秀青年科学基金。现任武汉大学口腔医(学)院党委委员、副院长,中华口腔医学会口腔医学教育专委会及口腔生物医学专委会常委,中华口腔医学会口腔颌面-头颈肿瘤专委会委员。近年来以第一或通信作者发表SCI论文50余篇,其中以唯一第一作者发表于Nature的研究发现了细胞外囊泡PD-L1在肿瘤免疫逃逸过程中的重要调控作用,揭示了肿瘤免疫治疗耐受的关键机制。主持国家自然科学基金5项,主持其他省部级基金5项。申请国家发明专利16项,获授权8项,完成科学技术成果转化1项。
基金资助:
国家自然科学基金专项项目(82341023)

Extracellular vesicles and oral tumor immunity

XIAO Bolin¹,ZHANG Wei^1,²,CHEN Gang^1,^2,³()

State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China

Revised:2023-07-02 Online:2023-09-28 Published:2023-09-28

摘要/Abstract

摘要：

细胞外囊泡是由细胞分泌的纳米级膜性小泡,是细胞间通信的重要载体。肿瘤细胞所分泌的细胞外囊泡不仅影响肿瘤的发生和发展,还可通过与免疫细胞的交互作用介导肿瘤免疫逃逸和治疗抵抗。基于细胞外囊泡的液体活检以及靶向细胞外囊泡的治疗策略在肿瘤治疗中具有较好的应用前景。该文阐述了细胞外囊泡的生物学特性及其在口腔肿瘤免疫调控和逃逸中的作用和机制,并探讨了基于细胞外囊泡的口腔肿瘤诊疗新策略,为推动细胞外囊泡的临床转化应用提供了理论依据。

关键词: 细胞外囊泡, 口腔肿瘤, 免疫细胞, 生物标志物, 免疫治疗

Abstract:

Extracellular vesicles are nanoscale membranous vesicles secreted by cells and are an important mediator for intercellular communication. Tumor-derived extracellular vesicles not only affect tumorigenesis and progression, but also mediate tumor immune escape and therapeutic resistance through interaction with immune cells. Liquid biopsies based on extracellular vesicles and therapeutic strategies targeting extracellular vesicles have promising applications in tumor therapy. This paper describes the biological properties of extracellular vesicles and their role in immune regulation of oral tumors, and discusses therapeutic strategies for oral tumors based on extracellular vesicles, providing a theoretical basis for promoting the clinical translation of extracellular vesicles.

Key words: extracellular vesicle, oral tumor, immune cell, biomarker, immunotherapy

中图分类号:

R739.8

肖博林, 张伟, 陈刚. 细胞外囊泡与口腔肿瘤免疫[J]. 口腔医学, 2023, 43(9): 769-774.

XIAO Bolin, ZHANG Wei, CHEN Gang. Extracellular vesicles and oral tumor immunity[J]. Stomatology, 2023, 43(9): 769-774.

图/表 2

参考文献 41

[1]	Muzio LL, Ballini A, Cantore S, et al. Overview of Candida albicans and human papillomavirus (HPV) infection agents and their biomolecular mechanisms in promoting oral cancer in pediatric patients[J]. Biomed Res Int, 2021, 2021: 7312611.
[2]	Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2022, 185(3):576. doi: 10.1016/j.cell.2022.01.008 pmid: 35120665
[3]	Ferris RL, Licitra L. PD-1 immunotherapy for recurrent or metastatic HNSCC[J]. Lancet, 2019, 394(10212):1882-1884. doi: S0140-6736(19)32539-5 pmid: 31679948
[4]	Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer[J]. Cell, 2023, 186(8):1610-1626. doi: 10.1016/j.cell.2023.03.010 pmid: 37059067
[5]	Chen G, Huang AC, Zhang W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response[J]. Nature, 2018, 560(7718):382-386. doi: 10.1038/s41586-018-0392-8
[6]	van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles[J]. Nat Rev Mol Cell Biol, 2018, 19(4):213-228. doi: 10.1038/nrm.2017.125
[7]	Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends[J]. J Cell Biol, 2013, 200(4):373-383. doi: 10.1083/jcb.201211138 pmid: 23420871
[8]	Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway[J]. Dev Cell, 2011, 21(1):77-91. doi: 10.1016/j.devcel.2011.05.015 pmid: 21763610
[9]	Stenmark H. Rab GTPases as coordinators of vesicle traffic[J]. Nat Rev Mol Cell Biol, 2009, 10(8):513-525. doi: 10.1038/nrm2728
[10]	Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018):A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines[J]. J Extracell Vesicles, 2018, 7(1):1535750. doi: 10.1080/20013078.2018.1535750
[11]	Dżaman K, Czerwaty K. Extracellular vesicle-based drug delivery systems for head and neck squamous cell carcinoma: A systematic review[J]. Pharmaceutics, 2023, 15(5):1327. doi: 10.3390/pharmaceutics15051327
[12]	Ludwig S, Sharma P, Theodoraki MN, et al. Molecular and functional profiles of exosomes from HPV(+) and HPV (-) head and neck cancer cell lines[J]. Front Oncol, 2018, 8: 445. doi: 10.3389/fonc.2018.00445 pmid: 30370252
[13]	Muller L, Mitsuhashi M, Simms P, et al. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets[J]. Sci Rep, 2016, 6: 20254. doi: 10.1038/srep20254 pmid: 26842680
[14]	Theodoraki MN, Yerneni SS, Hoffmann TK, et al. Clinical significance of PD-L1⁺ exosomes in plasma of head and neck cancer patients[J]. Clin Cancer Res, 2018, 24(4):896-905. doi: 10.1158/1078-0432.CCR-17-2664
[15]	Hadavand M, Hasni S. Exosomal biomarkers in oral diseases[J]. Oral Dis, 2019, 25(1):10-15. doi: 10.1111/odi.12878 pmid: 29688608
[16]	Maybruck BT, Pfannenstiel LW, Diaz-Montero M, et al. Tumor-derived exosomes induce CD8⁺ T cell suppressors[J]. J Immunother Cancer, 2017, 5(1):65. doi: 10.1186/s40425-017-0269-7 pmid: 28806909
[17]	Xiao BL, Wang XL, Xia HF, et al. HRS regulates small extracellular vesicle PD-L1 secretion and is associated with anti-PD-1 treatment efficacy[J]. Cancer Immunol Res, 2023, 11(2):228-240. doi: 10.1158/2326-6066.CIR-22-0277
[18]	Bellmunt ÀM, López-Puerto L, Lorente J, et al. Involvement of extracellular vesicles in the macrophage-tumor cell communication in head and neck squamous cell carcinoma[J]. PLoS One, 2019, 14(11):e0224710. doi: 10.1371/journal.pone.0224710
[19]	Xiao M, Zhang JJ, Chen WJ, et al. M1-like tumor-associated macrophages activated by exosome-transferred THBS1 promote malignant migration in oral squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1):143. doi: 10.1186/s13046-018-0815-2 pmid: 29986759
[20]	Tong FJ, Mao XH, Zhang SW, et al. HPV⁺ HNSCC-derived exosomal miR-9 induces macrophage M1 polarization and increases tumor radiosensitivity[J]. Cancer Lett, 2020, 478: 34-44. doi: 10.1016/j.canlet.2020.02.037
[21]	Wang YN, Qin X, Zhu XQ, et al. Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway[J]. Oral Oncol, 2018, 76:34-41. doi: 10.1016/j.oraloncology.2017.11.024
[22]	Ludwig S, Floros T, Theodoraki MN, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer[J]. Clin Cancer Res, 2017, 23(16):4843-4854. doi: 10.1158/1078-0432.CCR-16-2819 pmid: 28400428
[23]	Asadirad A, Hashemi SM, Baghaei K, et al. Phenotypical and functional evaluation of dendritic cells after exosomal delivery of miRNA-155[J]. Life Sci, 2019, 219:152-162. doi: S0024-3205(19)30005-0 pmid: 30625290
[24]	Zhao ZJ, Zhang HY, Zeng Q, et al. Exosomes from 5-aminolevulinic acid photodynamic therapy-treated squamous carcinoma cells promote dendritic cell maturation[J]. Photodiagnosis Photodyn Ther, 2020, 30: 101746. doi: 10.1016/j.pdpdt.2020.101746
[25]	Li L, Cao BR, Liang XH, et al. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral γδ T cell equilibrium via tumor-derived exosomes[J]. Oncogene, 2019, 38(15):2830-2843. doi: 10.1038/s41388-018-0627-z
[26]	Schroeder JC, Puntigam L, Hofmann L, et al. Circulating exosomes inhibit B cell proliferation and activity[J]. Cancers(Basel), 2020, 12(8):2110.
[27]	Hoshino A, Kim HS, Bojmar L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers[J]. Cell, 2020, 182(4):1044-1061.e18. doi: S0092-8674(20)30874-6 pmid: 32795414
[28]	Theodoraki MN, Hoffmann TK, Whiteside TL. Separation of plasma-derived exosomes into CD3⁽⁺⁾ and CD3^(-)fractions allows for association of immune cell and tumour cell markers with disease activity in HNSCC patients[J]. Clin Exp Immunol, 2018, 192(3):271-283. doi: 10.1111/cei.13113 pmid: 29431869
[29]	Li Y, Chen ZK, Duan X, et al. Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer[J]. Exp Mol Med, 2022, 54(9):1379-1389. doi: 10.1038/s12276-022-00856-3 pmid: 36117219
[30]	Liu T, Chen G, Sun DW, et al. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma[J]. Acta Biochim Biophys Sin, 2017, 49(9):808-816. doi: 10.1093/abbs/gmx078
[31]	Li RW, Zhou YF, Zhang MM, et al. Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway[J]. Int Immunopharmacol, 2023, 118: 110094. doi: 10.1016/j.intimp.2023.110094
[32]	Orme JJ, Enninga EAL, Lucien-Matteoni F, et al. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles[J]. J Immunother Cancer, 2020, 8(2):e001113. doi: 10.1136/jitc-2020-001113
[33]	Shin S, Ko H, Kim CH, et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy[J]. Nat Mater, 2023, 22(5):656-665. doi: 10.1038/s41563-023-01515-2 pmid: 36959501
[34]	Wu PP, Zhang B, Ocansey DKW, et al. Extracellular vesicles: A bright star of nanomedicine[J]. Biomaterials, 2021, 269: 120467. doi: 10.1016/j.biomaterials.2020.120467
[35]	Yang TZ, Martin P, Fogarty B, et al. Exosome delivered antican-cer drugs across the blood-brain barrier for brain cancer therapy in Danio rerio[J]. Pharm Res, 2015, 32(6):2003-2014. doi: 10.1007/s11095-014-1593-y
[36]	Wang CH, Chen L, Huang YY, et al. Exosome-delivered TRPP2 siRNA inhibits the epithelial-mesenchymal transition of FaDu cells[J]. Oncol Lett, 2019, 17(2):1953-1961. doi: 10.3892/ol.2018.9752 pmid: 30675260
[37]	Kase Y, Uzawa K, Wagai S, et al. Engineered exosomes deliver-ing specific tumor-suppressive RNAi attenuate oral cancer progression[J]. Sci Rep, 2021, 11(1):5897. doi: 10.1038/s41598-021-85242-1
[38]	Wu M, Chen ZK, Xie QH, et al. One-step quantification of salivary exosomes based on combined aptamer recognition and quantum dot signal amplification[J]. Biosens Bioelectron, 2021, 171: 112733. doi: 10.1016/j.bios.2020.112733
[39]	Dong HY, Xie QH, Pang DW, et al. Precise selection of aptamers targeting PD-L1 positive small extracellular vesicles on magnetic chips[J]. Chem Commun(Camb), 2021, 57(29):3555-3558.
[40]	Xu R, Yu ZL, Liu XC, et al. Aptamer-assisted traceless isolation of PD-L1-positive small extracellular vesicles for dissecting their subpopulation signature and function[J]. Anal Chem, 2023, 95(2):1016-1026.
[41]	Yu ZL, Liu XC, Wu M, et al. Untouched isolation enables targe-ted functional analysis of tumour-cell-derived extracellular vesicles from tumour tissues[J]. J Extracell Vesicles, 2022, 11(4):e12214. doi: 10.1002/jev2.v11.4

细胞外囊泡与口腔肿瘤免疫

Extracellular vesicles and oral tumor immunity

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 41

相关文章 14

编辑推荐

Metrics

本文评价

[1]	孙乐章,王琪. 高糖水平下牙周组织的形态与免疫特征[J]. 口腔医学, 2023, 43(2): 153-158.
[2]	徐英娇, 王姗. 唾液外泌体在口腔鳞状细胞癌的研究进展[J]. 口腔医学, 2022, 42(7): 664-667.
[3]	沙莎, 陆玲波, 郭培培, 陈姝, 靳牧涵, 徐荣耀. 唾液细胞外囊泡miRNA-143/145与雌激素缺乏性骨质疏松相关性的临床研究[J]. 口腔医学, 2022, 42(6): 515-520.
[4]	赵宇琪, 田胜兰, 李莹, 王爱芹. 活化型基质金属蛋白酶-8作为牙周生物标志物的研究进展[J]. 口腔医学, 2022, 42(4): 373-376.
[5]	费凡王雨萌韩冰. 外泌体调控口腔鳞状细胞癌发生发展[J]. , 2021, 41(11): 1034-1038.
[6]	赵昊明赵华强. B7H5于口腔颌面头颈肿瘤免疫治疗中作为联合用药靶点的应用潜力探究[J]. , 2018, 38(11): 1048-1052.
[7]	高继宾,李兴平,王琦,蒋继党. 颊脂垫修复口腔肿瘤缺损的临床观察[J]. , 2010, 30(01): 56-57.
[8]	陈洁,张红闯,宋晓萌,叶金海,吴煜农. Nrp1、Nrp2及SEMA3F在口腔癌组织及TCa、ACC细胞系中的表达及其可能的作用[J]. , 2009, 29(5): 235-238.
[9]	蒋蕾,陈洁,张红闯,宋晓萌,吴煜农. SEMA 3A及其受体NRP-1及Plexin A1在口腔癌中的表达及其可能的作用[J]. , 2009, 29(11): 564-567.
[10]	刘治慧;刘建华;吴求亮. 胸锁乳突肌肌皮瓣在肿瘤术后口底缺损修复中的应用[J]. , 2006, 26(4): 301-302.
[11]	曾东林,王国华,廖煜. 经颞浅动脉灌注氟尿嘧啶和卡铂治疗舌癌[J]. , 2005, 25(6): 351-352.
[12]	章永平,陈关福,钟来平,张行. 口腔及涎腺癌患者唾液与血清中CEA和CA-50含量的研究[J]. , 2002, 22(03): 125-127.
[13]	陈光,贺占国,王琪,王永海,成继民. 毛细血管瘤组织中免疫细胞的分布变化及其意义[J]. , 2000, 20(1): 14-15.
[14]	马志君；吴瑞琼. 口腔颌面肿瘤患者血清唾液酸的测定[J]. , 1997, 17(3): 123-124.